Literature DB >> 11006034

Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells.

M Huang1, C Page, R K Reynolds, J Lin.   

Abstract

OBJECTIVE: Stat 3 functions in transducing signals from the cell's surface to its nucleus and activation of gene transcription. Aberrations of Stat 3 in breast cancer have raised the possibility of its contribution to oncogenesis. Our goal was to examine ovarian cancer cell lines to determine whether Stat 3 plays a relevant role in ovarian carcinogenesis.
METHODS: Protein lysates were extracted from normal ovarian surface epithelial cells and malignant cells. Western blotting techniques were performed with phosphorylation-independent or phosphorylation-specific Stat 3 (tyrosine 705) antibody. Confirmation of Stat 3 activation was determined by a luciferase reporter driven by a promoter containing Stat 3-specific binding sites. Bcl-x(L) and cyclin D(1) were also analyzed by Western blotting.
RESULTS: MDAH 2774, OV-1063, Caov-3, and O.C. 22819 expressed high levels of phosphorylated Stat 3. In contrast, A2780 and normal ovarian surface epithelial cells had little Stat 3 phosphorylation recognized. Confirmation of persistent activation of Stat 3 activity was shown by transfection of cells with a Stat 3 luciferase reporter. Potential downstream mediators of Stat 3 including Bcl-x(L) and cyclin D(1) were also evaluated. In cells expressing activated Stat 3, high levels of both Bcl-x(L) and cyclin D(1) were detected, whereas in A2780 cells, which did not express activated Stat 3, only low levels of Bcl-x(L) and cyclin D(1) were expressed.
CONCLUSIONS: Constitutive activation of Stat 3 is present in ovarian cancer lines but not in normal ovarian surface epithelial cells. Activation of Stat 3 is a common event during oncogenic transformation upstream to both Bcl-x(L) and cyclin D(1). The relationship of this aberrancy of ovarian carcinoma harboring activated Stat 3 deserves further investigation. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006034     DOI: 10.1006/gyno.2000.5931

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  64 in total

1.  JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma.

Authors:  Zhenbing You; Dafu Xu; Jian Ji; Wei Guo; Weiguo Zhu; Jingdong He
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

2.  STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer.

Authors:  Jing-Yu Deng; Dan Sun; Xiang-Yu Liu; Yi Pan; Han Liang
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 3.  Suppressors of cytokine signaling in health and disease.

Authors:  Jane C Tan; Ralph Rabkin
Journal:  Pediatr Nephrol       Date:  2005-02-19       Impact factor: 3.714

Review 4.  Embryonic stem cell-specific signature in cervical cancer.

Authors:  Jorge Organista-Nava; Yazmín Gómez-Gómez; Patricio Gariglio
Journal:  Tumour Biol       Date:  2013-10-28

5.  Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer.

Authors:  Jennifer Dien; Hesham M Amin; Neil Chiu; Winson Wong; Christine Frantz; Brian Chiu; John R Mackey; Raymond Lai
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

6.  The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate.

Authors:  Ravi P Sahu; Sanjay K Srivastava
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

7.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.

Authors:  Paul L Leong; Genevieve A Andrews; Daniel E Johnson; Kevin F Dyer; Sichuan Xi; Jeffrey C Mai; Paul D Robbins; Seshu Gadiparthi; Nancy A Burke; Simon F Watkins; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

8.  Activation of Stat3 in renal tumors.

Authors:  Charles Guo; Guanyu Yang; Kyle Khun; Xiantian Kong; David Levy; Peng Lee; Jonathan Melamed
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

9.  STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination.

Authors:  Joo Eun Jung; Hong Sook Kim; Chang Seok Lee; Yong Jae Shin; Yong Nyun Kim; Gyeong Hoon Kang; Tae You Kim; Yong Sung Juhnn; Sung Joon Kim; Jong Wan Park; Sang Kyu Ye; Myung Hee Chung
Journal:  Exp Mol Med       Date:  2008-10-31       Impact factor: 8.718

10.  Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.

Authors:  Galina Gritsina; Fang Xiao; Shane W O'Brien; Rashid Gabbasov; Marisa A Maglaty; Ren-Huan Xu; Roshan J Thapa; Yan Zhou; Emmanuelle Nicolas; Samuel Litwin; Siddharth Balachandran; Luis J Sigal; Dennis Huszar; Denise C Connolly
Journal:  Mol Cancer Ther       Date:  2015-02-02       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.